[The pharmacokinetics of the prolonged-action beta-adrenoblocker nadolol in hypertension patients after a single administration].
The pharmacokinetics of the beta-adrenoceptor blocker nadolol was studied in 30 patients suffering from mild hypertension given a single 80 mg dose of the drug. It has been shown that distribution of the pharmacokinetic parameters in this sample can be assumed normal. Their averages are similar to the reported data on healthy subjects. The mean retention time of nadolol in the body was estimated for the first time. The absorption of the drug was shown to be slow, which together with a low degree of bioavailability, may be associated with its low lipophility. A close correlation was demonstrated between the half-life and the mean absorption time estimates computed from blood serum and nadolol excretion with urine. The conclusion is made that glomerular filtration plays the key role in the drug elimination.
Poteshnykh
A V
AV
Piotrovskiĭ
V K
VK
Metelitsa
V I
VI
Filatova
N P
NP
Ostrovskaia
T P
TP
D000284:Administration, Oral; D000328:Adult; D003404:Creatinine / Q000652:urine; D003692:Delayed-Action Preparations; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009248:Nadolol / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D013997:Time Factors
D003692:Delayed-Action Preparations; D009248:Nadolol; D003404:Creatinine
Farmakokinetika beta-adrenoblokatora prolongirovannogo deĭstviia nadolola u bol'nykh gipertonicheskoĭ bolezn'iu posle odnokratnogo priema.